BDTX
Price
$1.61Alerts
Change
+$0.01 (+0.62%)
Updated
Nov 11 closing price
Capitalization
99.68M
132 days until earnings call
Intraday BUY SELL Signals
NAMS
Price
$20.72Alerts
Change
+$1.54 (+8.03%)
Updated
Nov 11 closing price
Capitalization
2.26B
111 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

BDTX vs NAMS

BDTX vs NAMS Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
BDTX vs. NAMS commentary
Nov 12, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BDTX is a Hold and NAMS is a Buy.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for BDTX with price predictions
Nov 11, 2026

BDTX's RSI Indicator ascending out of oversold territory

The RSI Indicator for BDTX moved out of oversold territory on October 14, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 34 similar instances when the indicator left oversold territory. In 29 of the 34 cases the stock moved higher. This puts the odds of a move higher at 85%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.

Following a +12.05% 3-day Advance, the price is estimated to grow further. Considering data from situations where BDTX advanced for three days, in 199 of 241 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on BDTX as a result. In 60 of 69 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 87%.

The Moving Average Convergence Divergence Histogram (MACD) for BDTX turned negative on November 10, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 42 similar instances when the indicator turned negative. In 38 of the 42 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.

BDTX moved below its 50-day moving average on October 23, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BDTX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

BDTX broke above its upper Bollinger Band on October 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for BDTX entered a downward trend on October 19, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 31 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.037) is normal, around the industry mean (3.498). P/E Ratio (-2.313) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (2.360) is also within normal values, averaging (440.869).

The Tickeron Price Growth Rating for this company is 80 (best 1 - 100 worst), indicating slightly worse than average price growth. BDTX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BDTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

A.I.Advisor
a Summary for NAMS with price predictions
Nov 11, 2026

NAMS in upward trend: price may jump up because it broke its lower Bollinger Band on October 13, 2026

NAMS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 35 of 43 cases where NAMS's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 81%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where NAMS's RSI Oscillator exited the oversold zone, 20 of 29 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 69%.

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 42 of 61 cases where NAMS's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 69%.

The Moving Average Convergence Divergence (MACD) for NAMS just turned positive on November 11, 2026. Looking at past instances where NAMS's MACD turned positive, the stock continued to rise in 40 of 58 cases over the following month. The odds of a continued upward trend are 69%.

Following a +9.05% 3-day Advance, the price is estimated to grow further. Considering data from situations where NAMS advanced for three days, in 202 of 251 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on NAMS as a result. In 61 of 93 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 66%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where NAMS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 78%.

The Aroon Indicator for NAMS entered a downward trend on November 11, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 13 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 29 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.578) is normal, around the industry mean (3.498). P/E Ratio (-8.750) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (357.143) is also within normal values, averaging (440.869).

The Tickeron Profit vs. Risk Rating rating for this company is 68 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NAMS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.

The Tickeron Price Growth Rating for this company is 81 (best 1 - 100 worst), indicating slightly worse than average price growth. NAMS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

FUNDAMENTALS RATINGS
BDTX: Fundamental Ratings
BDTX
OUTLOOK RATING
1..100
41
VALUATION
overvalued / fair valued / undervalued
1..100
31
Undervalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
97
PRICE GROWTH RATING
1..100
80
P/E GROWTH RATING
1..100
98
SEASONALITY SCORE
1..100
85

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
BDTXNAMS
RSI
ODDS (%)
Bullish Trend 1 day ago
85%
Bullish Trend 1 day ago
69%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
82%
Bullish Trend 1 day ago
69%
Momentum
ODDS (%)
Bearish Trend 1 day ago
87%
Bearish Trend 1 day ago
66%
MACD
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
69%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
71%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
88%
Bearish Trend 1 day ago
73%
Advances
ODDS (%)
Bullish Trend 4 days ago
83%
Bullish Trend 1 day ago
80%
Declines
ODDS (%)
Bearish Trend 11 days ago
90%
Bearish Trend 11 days ago
78%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
85%
Bullish Trend 1 day ago
81%
Aroon
ODDS (%)
Bearish Trend 1 day ago
86%
Bearish Trend 1 day ago
82%
COMPARISON
Comparison
Nov 12, 2026
Stock price -- (BDTX: $1.61 vs. NAMS: $20.72)
Brand notoriety: BDTX and NAMS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BDTX: 115% vs. NAMS: 178%
Market capitalization -- BDTX: $99.68M vs. NAMS: $2.26B
BDTX [@Biotechnology] is valued at $99.68M. NAMS’s [@Biotechnology] market capitalization is $2.26B. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $138.67B. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BDTX’s FA Score shows that 1 FA rating(s) are green while NAMS’s FA Score has 2 green FA rating(s).

  • BDTX’s FA Score: 1 green, 4 red.
  • NAMS’s FA Score: 2 green, 3 red.
According to our system of comparison, NAMS is a better buy in the long-term than BDTX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BDTX’s TA Score shows that 3 TA indicator(s) are bullish while NAMS’s TA Score has 5 bullish TA indicator(s).

  • BDTX’s TA Score: 3 bullish, 6 bearish.
  • NAMS’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, NAMS is a better buy in the short-term than BDTX.

Price Growth

BDTX (@Biotechnology) experienced а -15.26% price change this week, while NAMS (@Biotechnology) price change was -1.00% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -0.49%. For the same industry, the average monthly price growth was -6.84%, and the average quarterly price growth was -13.86%.

Reported Earning Dates

BDTX is expected to report earnings on Mar 24, 2027.

NAMS is expected to report earnings on Mar 03, 2027.

Industries' Descriptions

@Biotechnology (-0.49% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
Interact to see
Advertisement

NAMS and

Correlation & Price change

A.I.dvisor indicates that over the last year, NAMS has been loosely correlated with SLDB. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if NAMS jumps, then SLDB could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NAMS
1D Price
Change %
NAMS100%
+8.03%
SLDB - NAMS
46%
Loosely correlated
+6.00%
VKTX - NAMS
45%
Loosely correlated
-0.77%
IMVT - NAMS
45%
Loosely correlated
+3.72%
FDMT - NAMS
43%
Loosely correlated
+4.25%
PTCT - NAMS
43%
Loosely correlated
+1.20%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
NANC49.690.66
+1.35%
Subversive Congressional Democrats Trading ETF (NANC)
YALL43.230.42
+0.98%
Truth Social God Bless America ETF (YALL)
POCT47.980.36
+0.76%
Innovator U.S. Equity Power Buffer ETF - October (POCT)
XEUR23.55N/A
N/A
Corgi Europe Equities 2x Daily ETF (XEUR)
MBSX25.80N/A
N/A
Regan Fixed Rate Mbs ETF